Compare IDEXX Laboratories, Inc. (IDXX) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Meta Platforms Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Meta Platforms Inc trades at $579.39 (market cap $1.53T). The key difference: Meta Platforms Inc is far larger — about 33.1× IDEXX Laboratories, Inc.'s market cap, and Meta Platforms Inc pays a 0.35% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | META | |
|---|---|---|
Market Cap | $46.22B | $1.53T |
Sector | Health | Media |
52-Week High | $766.68 | $790.00 |
52-Week Low | $526.44 | $525.72 |
Enterprise Value | $47.12B | $1.55T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
META trades at $579.51, down 2.59% in 24 hours, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $200.97B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a legal ruling in Massachusetts regarding youth addiction lawsuits.
The outlook remains positive with a consensus price target of $761.95 and 79% buy ratings from analysts, driven by AI innovation and solid fundamentals. Risks include regulatory challenges and high capital expenditures, but earnings beats and institutional buying support long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
